Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31223090 | 0.89 | DRD2 (0.58) | LPLLIPGDRD2 | |
| SCHEMBL15774976 | 0.85 | SLC18A3 (0.55) | LPLLIPGDRD2HIF1AF11 | |
| SCHEMBL22804541 | 0.85 | DRD2 (0.43) | LPLLIPGDRD2HIF1A | |
| SCHEMBL23291582 | 0.84 | LPL (0.42) | LPLLIPGDRD2HIF1A | |
| SCHEMBL4384473 | 0.84 | LPL (0.39) | LPLLIPGDRD2HIF1AF11 | |
| SCHEMBL578423 | 0.84 | QDPR (0.44) | LPLLIPGHIF1A | |
| SCHEMBL14804365 | 0.83 | LPL (0.52) | LPLLIPGHIF1AF11 | |
| SCHEMBL16112310 | 0.83 | LPL (0.52) | LPLLIPGHIF1AF11 | |
| SCHEMBL22804954 | 0.83 | SLC18A3 (0.41) | LPLLIPGDRD2HIF1AF11 | |
| SCHEMBL22806317 | 0.83 | DRD2 (0.45) | LPLLIPGDRD2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-12552801-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024187126-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | AQUINNAH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2024-05-16 | — | — | US | disclosed |
| US-20240059692-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4285996-A2 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023198114-A1 | ALK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2023-10-19 | — | — | WO | disclosed |
| US-9434726-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-09-06 | — | — | US | disclosed |
| US-9434726-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-09-06 | — | — | US | disclosed |
| US-8895583-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| EP-2718293-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | Hutchison Medipharma Limited (CN) | 2014-04-16 | — | — | EP | disclosed |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012167733-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012167733-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | LPL 2658/4885LIPG 954/4885DRD2 4568/4885 |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A1, GUCY1A2 | LPL 773/4885LIPG 80/4885DRD2 3392/4885 |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | SYK, BTK, LYN | LPL 3662/4885LIPG 3203/4885DRD2 1350/4885 |
| US-20240059692-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, ABCB11, CYP3A7 | LPL 4682/4885LIPG 4709/4885DRD2 1294/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | LPL 3096/4885LIPG 2312/4885DRD2 807/4885 |
| US-12552801-B2 | Indazole derivatives | EGFR, ABL1, ERBB3 | LPL 3205/4885LIPG 4156/4885DRD2 667/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | LPL 4600/4885LIPG 1994/4885DRD2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.